On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…
Focus on PROTAC—Target Summary from 2001 to 2019
PROTAC, of which the full name is proteolysis-targeting chimera, looks like a dumbbell and mainly consists of a linker, a ligand of interest protein, and a ligand recruiting E3 ubiquitin ligase. InRead More…
Basic Research Progress of PROTAC in Hematological Diseases-Part Two
In addition to the T-cell Lymphoma,T-cell Acute Lymphoblastic Leukaemia mentioned in our previous article, there are also related studies of protac in other blood diseases. Next, let’s analyze the research of protacRead More…
Basic Research Progress of PROTAC in Hematological Diseases-Part one
Proteolysis targeted chimera (PROTAC) is a rapidly developed technology in recent years, which provides the possibility for many undruggable targets, and has become the focus of protein drug researchers. Hematologic malignancies areRead More…
Advantages and Challenges of PROTAC Technology in Drug Discovery
In recent years, targeted protein degradation chimera (PROTAC) as a novel way to induce protein degradation has become a new drug discovery strategy. Compared with traditional protein inhibitor drugs, it has uniqueRead More…
Ocogene: Novel Anticancer Therapeutics-PROTAC
PROTACs is a novel technique in protein drug research field. Unlike traditional protein inhibitors, PROTACs are potential to target undruggable protein. Therefore, it has become a potential cancer therapy strategy. PROTACs appearsRead More…
Protacs: STAT3 specific small molecule degradant inhibits tumor growth
Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family, which responds to a variety of cytokines, growth factors and other signals and activates the expression ofRead More…
The First PROTAC Drug ARV-110’s Latest Clinical Data: Preliminary Display of Anti-tumor Activity
Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…